Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 144

Results For "MP"

10739 News Found

AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%
Clinical Trials | May 25, 2026

AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%

The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial


Zota Health Care posts 83.86% revenue surge in FY26
Healthcare | May 25, 2026

Zota Health Care posts 83.86% revenue surge in FY26

Expands Davaindia network to 2,579 stores


EU regulator backs Allergan Aesthetics’ Boey in key step toward approval
Drug Approval | May 25, 2026

EU regulator backs Allergan Aesthetics’ Boey in key step toward approval

The decision marks a key step in the centralized EU review process


AbbVie signals major oncology momentum at ASCO
R&D | May 25, 2026

AbbVie signals major oncology momentum at ASCO

With standout ADC and t-cell engager response data across hard-to-treat cancers


AstraZeneca to showcase cancer pipeline push at ASCO 2026
R&D | May 25, 2026

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies


Sumitomo Pharma unveils new COURAGE & OPTYX data at AUA 2026
R&D | May 25, 2026

Sumitomo Pharma unveils new COURAGE & OPTYX data at AUA 2026

Highlights strong Vibegron results in older men & real-world prostate cancer insights


Enveric reports key safety milestone for EB-003 reinforcing clinical development path
Biotech | May 25, 2026

Enveric reports key safety milestone for EB-003 reinforcing clinical development path

The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors


Fortis Healthcare  FY26 revenue crosses Rs. 9,100 crore
Hospitals | May 23, 2026

Fortis Healthcare FY26 revenue crosses Rs. 9,100 crore

Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum


Health ministry classifies Pregabalin under Schedule H1 to curb misuse
Policy | May 23, 2026

Health ministry classifies Pregabalin under Schedule H1 to curb misuse

New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain


Shreevar Kheruka appointed Managing Director at Borosil Limited
People | May 23, 2026

Shreevar Kheruka appointed Managing Director at Borosil Limited

Kheruka has played a key role in transforming Borosil into a diversified, international consumer-focused enterprise